Table 1 The functions of m6A regulators in therapy resistance
From: The role of m6A methylation in therapy resistance in cancer
Therapy type | Drug | Cancer | Regulator | Regulation | Target/Approach | References |
|---|---|---|---|---|---|---|
Chemo- therapy | Cisplatin | Ovarian Cancer | ALKBH5 | PR | JAK2/STAT3 | 29 |
| Â | Â | Bladder Cancer | ALKBH5 | PR | CK2 | 30 |
| Â | Â | OSCC | ALKBH5 | PR | FOXM1/NANOG | 32 |
| Â | Â | Bladder Cancer | WTAP | PR | Circ0008399/TNFAIP3 | 33 |
| Â | Â | NKTCL | WTAP | PR | DUSP6 | 34 |
| Â | Â | Seminoma | METTL3 | PR | ATG5/Autophagy | 36 |
| Â | Â | Seminoma | METTL3 | PR | TFAP2C | 37 |
| Â | Â | Seminoma | KIAA1429 | PR | DNA damage response | 38 |
| Â | Â | Pancreatic Cancer | METTL3 | PR | MAPK | 39 |
| Â | Â | CRC | YTHDF1 | PR | GLS1 | 40 |
| Â | Â | Ovarian Cancer | YTHDF1 | PR | TRIM29 | 41 |
| Â | Â | Cholangio-carcinoma | YTHDF2 | PR | CDKN1B | 43 |
| Â | Â | Cervical Cancer | YTHDF2 | PR | AXIN1 | 44 |
| Â | Adriamycin | Breast Cancer | METTL3 | PR | miR-221-3p/HIPK2 | 46 |
| Â | Â | Breast Cancer | METTL3 | PR | EGF/RAD51 | 47 |
| Â | Â | Breast Cancer | METTL3 | PR | MALAT1/E2F1/AGR2 | 48 |
| Â | Â | Breast Cancer | ALKBH5 | PR | BRCA1 | 49 |
| Â | Â | Breast Cancer | FTO | PR | STAT3 | 50 |
| Â | Gemcitabine | Pancreatic Cancer | ALKBH5 | PR | WIF-1 | 51 |
| Â | Â | Pancreatic Cancer | METTL14 | PR | CDA | 52 |
| Â | Â | Pancreatic Cancer | METTL3 | PR | DBH-AS1/miR-3163/USP44 | 53 |
| Â | Â | Pancreatic Cancer | ZC3H13 | PR | PHF10 | 54 |
|  |  | CRC | METTL3 | PR | Wnt/β-catenin | 55 |
| Â | Â | CRC | YTHDF1 | PR | c-Myc | 56 |
| Â | Â | CRC | METTL3 | PR | miR-181d-5p | 57 |
Targeted-therapy | Erlotinib | Lung- adenocarcinoma | METTL3 | PR | miR-146a/Notch | 58 |
| Â | Â | Lung- adenocarcinoma | YTHDF2 | PR | TUSC7 | 58 |
| Â | TKIs | Â | FTO | PR | - | 61 |
| Â | Imatinib | CML | METTL3/METTL14 | PR | - | 63 |
| Â | PLX4032 | Melanoma | METTL3 | PR | RAF/MEK/ERK | 64 |
| Â | Sorafenib | HCC | METTL3 | PR | FOXO3 | 69 |
Immuno-therapy | PD-L1 | NSCLC | METTL3 | PR | circIGF2BP3/ PKP3/OTUB1 | 71 |
| Â | Â | Bladder Cancer | METTL3 | PR | JNK pathway | 72 |
|  | PD-1 | CRC | METTL3/METTL14 | PR | IFN-γ-Stat1-Irf1 | 73 |
| Â | PD-1 | Melanoma | FTO | PR | PD-1/CXCR4/SOX10 | 74 |
| Â | PD-1 | Melanoma | ALKBH5 | PR | Mct4/Slc16a3 | 75 |
Radio-therapy | Â | GBM | METTL3 | PR | GSC/DNA repair | 76 |
| Â | Â | GBM | ALKBH5 | PR | GSC/HR | 77 |
|  |  | Cervical Cancer | FTO | PR | β-catenin/ ERCC1 | 78 |
| Â | Â | HSCC | METTL3 | PR | circCUX1/Caspase 1 | 79 |
| Â | Â | NPC | YTHDC2 | PR | IGF1R/ PI3K-AKT/S6 | 80 |